EVADE Study

[EVADE Study @EvadeStudy]

Thank you for your patience! Results from EVADE can be found here:
https://t.co/N92oRlJtaw
Thank you to all those who contributed!

[EVADE Study @EvadeStudy]

@wmasjoshmiller @swasFT @swasftResearch Will continue to be available for routine use pending results and discussion with @swasFT while stocks last. We hope to consider an ongoing service evaluation if supported by @EvadeStudy findings.

[EVADE Study @EvadeStudy]

It's the last day of @EvadeStudy recruitment! With a predicted recruitment of over 800 participants @swasFT and @swasftResearch have done an amazing job! Still time to use the VAD for your #svt patients and if evidence of benefit we hope the device will continue to be available

[EVADE Study @EvadeStudy]

Thank you to all those that have contributed to the trial and especially to @swasFT and @swasftResearch staff. Even in the face of a cyber attack you have smashed it!😍

[EVADE Study @EvadeStudy]

@swasFT @NIHRSW @UniofExeter @RoyalDevonNHS Can't remember exactly how to do a modified Valsalva for #SVT ? It's written on the device. Please use for all VMs @swasFT

[EVADE Study @EvadeStudy]

@swasFT @NIHRSW @UniofExeter @RoyalDevonNHS Thank you @swasFT and @swasftResearch . Now in the last phase of this trial whereby the device is available for routine use across the trust. #Itsinthegreenresponsebag #svt

[South Western Ambulance Service @swasFT]

#TeamSWASFT is trialling a new device for our patients with an abnormally fast heart rhythm which could help reduce hospital admissions across the #SouthWest.💚

Read more about the study here ▶️https://t.co/GlymO7nKXl

[EVADE Study @EvadeStudy]

Very exciting final stage of @EvadeStudy where by all 100% @swasFT ambulance station clinicians will have access to the Valsalva Assist Device to treat #SVT. Great work by @swasftResearch, @ExeterCTU and @NIHRSW to reach this stage. Approaching 600 patients treated!

[EVADE Study @EvadeStudy]

and the support and expertise of @ExeterCTU . Thank you 🙏

[EVADE Study @EvadeStudy]

https://t.co/LeZuFv0cDF
Delighted that our EVADE SVT protocol paper has been published open access. Designing a pragmatic study for delivery during normal ambulance care by usual treating @swasFT clinicians has been challenging and rewarding. @swasftResearch @NIHRSW

[EVADE Study @EvadeStudy]

This would not have been possible without our fantastic station champions and @swasftResearch staff. Look forward to seeing what we can achieve!

[EVADE Study @EvadeStudy]

Dream recruitment continues! Thank you @swasFT and @swasftResearch. What an amazing job.
50% of crews can now use the VAD as standard and we hope this will help you in treating your #SVT patients

[EVADE Study @EvadeStudy]

@EcgsOnly If stable, the patient could be treated with a modified Valsalva Manoeuvre and if treated by @swasFT would be in the #EVADESVT trial. Half of all ambulance stations in this region now have access to a Valsalva Assist Device (VAD) as standard

[EVADE Study @EvadeStudy]

As of 1st March, half of all @swasFT ambulance stations now have access to the Valsalva Assist Device (VAD) as the routine device to treat #SVT. If it's in the pouch you can use it! #JustaccesstheValsalvapouch @swasftResearch

[EVADE Study @EvadeStudy]

Thank you to all the @swasFT stations that are contributing to our trial. Mugs on their way to stations that treated the 1st, 100th, 200th and 300th patients, plus a prize draw each month. Who will get 400th? @swasftResearch. Love to see pics of your mugs

[EVADE Study @EvadeStudy]

Congratulations Honiton @swasFT Ambulance station which treated the 300th EVADE SVT patient! Well done. Another 25% of stations will have access to the VAD in March. #accessthepouch #svt #vad

https://t.co/XnfRiErjwZ

[EVADE Study @EvadeStudy]

Nearly 300 participants recruited to the EVADE SVT study by @swasFT in just 7 months!Amazing effort! EVADE is designed to see if a simple device can reduce conveyance in SVT. Which station will treat the 300th? @swasftResearch @NIHRSW

[EVADE Study @EvadeStudy]

@Aidan_Baron @swasFT @swasftResearch A 10% point reduction in hospital conveyance, for which EVADE is powered to detect, would pay for devices for an entire ambulance trust within 7 months. Given the delays ambulances are currently experiencing at EDs there are the wider benefits of avoiding convayance too.

[EVADE Study @EvadeStudy]

Excited that as of 1st Nov the Valsalva Assist Device (VAD) will become available to @swasFT paramedics for routine treatment of #SVT. In the @EvadeStudy randomly selected stations will have the VAD stocked on ambulances and devices rolled out to all stations over next 18 months

[EVADE Study @EvadeStudy]

@Aidan_Baron @swasFT @swasftResearch No. The VAD enables a reliable and pressure controlled strain and includes instructions for an evidence based VM, easily available to paramedics who may rarely perform a VM. We shall see if this has any benefits over a syringe - That is the point of trial!